Thank you for your email. As is our practice, we will continue to make public all relevant, material developments including financing and progress on future plans. As far as I’m aware, the Company has not said it will publish any meeting notes with the FDA. However, we presume that any future correspondence from regulators would be related to confirmation or not of our breakthrough status filing; again, any material developments are expected to be shared when known.